Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Akari Therapeutics ( (AKTX) ) just unveiled an announcement.
On December 15, 2025, Akari Therapeutics held a Special General Meeting where shareholders approved several resolutions, including the exercisability of certain warrants and the issuance of ordinary shares related to a previous securities offering. The meeting also resulted in the approval of a share subdivision, authorization for directors to allot shares, and a share buyback contract, which are expected to impact the company’s financial structure and shareholder value positively.
The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company focused on developing treatments for rare and orphan diseases. The company primarily works on therapies targeting complement and leukotriene pathways, which are involved in immune and inflammatory responses.
Average Trading Volume: 738,840
Technical Sentiment Signal: Sell
Current Market Cap: $12.7M
Learn more about AKTX stock on TipRanks’ Stock Analysis page.